The drug, which is estimated to be taken by up to 750,000 people, is one of the country's most popular weight loss and ...

Serena Williams' revelation on Thursday that she'd lost 31 pounds came with another confession. Fans were angered with ...

GLP-1 meds are trending after Serena Williams’ 31-pound weight loss. A doctor breaks down the side effects, safety concerns & ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Tennis star Serena Williams' candor about her GLP-1 use may help dispel the pesky health inaccuracy that weight loss is a ...

Serena Williams has revealed she lost 31 pounds on the GLP-1 Zepbound: "I just couldn't get my weight to where I needed to be at a healthy place." ...

People with type 2 diabetes treated with GLP-1 receptor agonists may face a slightly higher risk for eye complications ...

The retired tennis pro explained that she’s trying to combat the stigma associated with weight loss drugs after losing 31 ...

A new imaging approach reveals how dual agonist drugs like tirzepatide act on the pancreas and brain to regulate blood sugar and appetite.

サノフィ株式会社（本社：東京都新宿区、代表取締役社長：岩屋孝彦、以下「サノフィ」）は、ステージ2の1型糖尿病の治療薬であるteplizumab（一般名）について、日本における最初の臨床試験「KIBOU-T1D」を開始し、最初の被験者の組み入れを完了し ...

Tennis champion Serena Williams has divided the internet after revealing she’s been using a GLP-1 weight loss drug. The ...